Please assess the completion status of the following clinical trial:

Trial Title: Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant has histologically documented advanced or metastatic malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available~* The participant has resolution of adverse events from prior anticancer therapies~* Performance status of 0 to 2~* The participant is ≥ 18 years of age~* The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing~* The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria~* The participant agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment~Exclusion Criteria:~* The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study~* The participant had therapeutic radiotherapy within 14 days prior to entering the study~* The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy~* The participant has brain or leptomeningeal metastases~* The participant has a history of uncontrolled or severe cardiac disease~* The participant has a history of severe congestive heart failure (CHF)~* The participant has a known history of arterial thrombotic events~* The participant has a known history of significant peripheral arterial disease (PAD)~* The participant has an implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)~* The participant has a history of risk factors for ventricular tachycardia or Torsades de pointes (TdP) \[for example, family history (parents or siblings) of long QT syndrome\], history of fainting, unexplained loss of consciousness, or convulsions~* The participant has a systolic blood pressure (SBP) of \> 150 millimeters of mercury (mmHg) or \< 90 mmHg or a diastolic blood pressure (DBP) of \< 45 or \> 95 mmHg. (Participants with a history of hypertension who are receiving antihypertensive therapy are permitted on study provided blood pressure is within the parameters detailed above)~* The participant has a heart rate \< 50 beats per minute (bpm) or \> 100 bpm at rest~* The participant has a clinically relevant abnormality on the ECG, preventing an accurate measurement of the QT interval~* The participant is using a medication that is known to prolong the ECG QT interval~* The participant has a known allergy to any of the treatment components including fluoroquinolone antibiotics~* The participant has received an investigational new drug or device within 14 days prior to enrollment into this study (excluding placement of an intravenous access device)~* The participant has undergone major surgery within 28 days prior to enrollment~* The participant has known human immunodeficiency virus (HIV) infection~* The participant, if female, is pregnant or lactating~* The participant is receiving chronic daily treatment with aspirin \[\> 325 milligrams per day (mg/day)\]~* The participant has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm~* The participant has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMC-1121B (Type: EXPERIMENTAL): Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab \[10 milligrams per kilogram (mg/kg)\] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between.

Based on this trial design, predict the completion outcome and termination type (if applicable).